Dr. Inadomi has specific expertise in screening and surveillance to reduce mortality from esophageal and colorectal cancers.
I have interests in understanding how patients make decisions about their health care. Specifically, it is my goal to increase completion of colorectal cancer screening tests, and I am focused on identifying the barriers to screening from a patient perspective.
I have specific expertise in screening and surveillance to reduce mortality from esophageal and colorectal cancers.
- Cyrus E. Rubin Professor and Head, Division of Gastroenterology, University of Washington School of Medicine
- Medical degree: University of California San Francisco
- Residency: University of California San Francisco
- Fellowship: University of California San Francisco
- Dr. Inadomi is the author of the American Gastroenterological Association (AGA) Guidelines for the Management of Barrett's Esophagus and has NIH funding to conduct comparative effectiveness research to reduce mortality from esophageal cancer.
- Dr. Inadomi was recognized as a 2013 "Top Doctor" in Seattle Met magazine's annual survey.
I have been a practicing gastroenterologist for 17 years and am experienced in many forms of endoscopy as well as clinic-based services.
As a systems engineer, John Inadomi realized that the most interesting and complex system was in fact the human body. "I decided to apply my skills to examine disease-specific problems from an engineering perspective," he says.
In gastroenterology, Dr. Inadomi explains that there are proven methods to reduce cancer mortality that rely upon early detection of pre-cancerous and cancerous lesions. "My role is to improve cancer screening by developing strategies that increase adherence to screening and surveillance strategies."
Dr. Inadomi's research has two major goals: 1) to identify barriers to colorectal cancer screening and develop/test/implement interventions to increase cancer screening; 2) conduct comparative effectiveness analysis to identify optimal strategies to reduce mortality from esophageal cancer.
In his lifetime, he hopes to see "improved stratification of risk so that we can target intervention to those most likely to benefit, and improved interventions so that we may prevent cancer instead of waiting for it to develop and then have to treat it."